• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, June 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Building a 3D model of ovarian cancer

Bioengineer by Bioengineer
March 2, 2014
in Cancer
Reading Time: 2 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The European Research Council (ERC) has awarded researchers at Barts Cancer Institute, Queen Mary University of London, a €2.43million grant for a project that aims to revolutionise the field of cancer cell research: using bioengineering techniques to grow the first complex 3D human tumour in the laboratory

Building a 3D model of ovarian cancer

Human cancers are more than just malignant cells, even at their very beginning. Other cells and chemicals that normally support and protect the body are hijacked by the cancer cells, instead helping the cancer to grow and spread.

Recent research has shown us the importance of targeting not only the malignant cancer cells but also this wider tumour microenvironment for long-term cancer treatment.

In the CANBUILD project, the multi-disciplinary team of scientists will be using the latest advances in tissue engineering, biomechanics, imaging and stem cell biology. They believe this combination will make it possible to engineer, for the first time, a complex 3D human tumour in which the different cell types making up the tumour microenvironment could communicate, evolve and grow in vitro (outside the body, in the laboratory).

The CANBUILD goal is to recreate the tumour microenvironment found in high-grade human ovarian cancer; the subtype that leads to 70 per cent of all ovarian cancer deaths. However, the research may have implications for several other cancer types as well.

The vision is that this project will replace traditional techniques in which human cancer cells are grown in isolation on plastic surfaces. Success in the CANBUILD project may also provide better ways of testing new drugs that target the human tumour microenvironment.

Professor Fran Balkwill, from Barts Cancer Institute, is Principal Investigator on the CANBUILD project. Professor Balkwill said:

“About half the cells in a tumour are not cancer cells, but ‘healthy’ cells such as immune cells and fibroblasts, which the cancer is somehow corrupting to help it grow and spread.

“It seems logical that the best long-term treatments will come from combining both therapies that target the cancer cells with something aimed at the wider tumour microenvironment which, while not cancerous cells themselves, are supporting the cancer’s growth.

“Growing an in vitro model, which contains all these types of cells, will allow us to watch how the cells communicate and how the tumour grows, teaching us more about what is going on in this complex system and hopefully giving us a model we can test new drugs on.”

The five-year research plan involves:

  • ‘Deconstruction’ of the human ovarian cancer tumour microenvironment
  • Constructing the artificial scaffold, optimising growth of different cell types, and assembling the model
  • Comparing the model to fresh human tissue
  • Investigating the roles of individual cells
  • Testing new treatments that target the tumour microenvironment
  • The ERC funding will also allow the team to communicate their research via the Centre of the Cell, Queen Mary’s award-winning science education centre and online resource, widening participation and outreach.

    Story Source:

    The above story is based on materials provided by Barts Cancer Institute.

    Share13Tweet8Share2ShareShareShare2

    Related Posts

    Dr. Alex Herrera

    Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

    June 4, 2023
    Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group

    The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

    June 3, 2023

    ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

    June 3, 2023

    For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

    June 2, 2023
    Please login to join discussion

    POPULAR NEWS

    • plants

      Plants remove cancer causing toxins from air

      40 shares
      Share 16 Tweet 10
    • Element creation in the lab deepens understanding of surface explosions on neutron stars

      36 shares
      Share 14 Tweet 9
    • Deep sea surveys detect over five thousand new species in future mining hotspot

      35 shares
      Share 14 Tweet 9
    • How life and geology worked together to forge Earth’s nutrient rich crust

      35 shares
      Share 14 Tweet 9

    About

    We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

    Follow us

    Recent News

    Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

    The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

    Carbon-based stimuli-responsive nanomaterials: classification and application

    Subscribe to Blog via Email

    Enter your email address to subscribe to this blog and receive notifications of new posts by email.

    Join 50 other subscribers
    • Contact Us

    Bioengineer.org © Copyright 2023 All Rights Reserved.

    No Result
    View All Result
    • Homepages
      • Home Page 1
      • Home Page 2
    • News
    • National
    • Business
    • Health
    • Lifestyle
    • Science

    Bioengineer.org © Copyright 2023 All Rights Reserved.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In